Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

M.W. Tang, S.Y. Rhee, S. Bertagnolio, N. Ford, S. Holmes, K.C. Sigaloff, R.L. Hamers, T.F. Rinke de Wit, H.J. Fleury, P.J. Kanki, K. Ruxrungtham, C.A. Hawkins, C.L. Wallis, W. Stevens, G.U. van Zyl, W. Manosuthi, M.C. Hosseinipour, N. Ngo-Giang-Huong, L. Belec, M. PeetersA. Aghokeng, T. Bunupuradah, S. Burdah, P. Cane, G. Cappelli, C. Charpentier, A.Y. Dagnra, A.K. Deshpande, Z. El-Katib, S.H. Eshleman, J. Fokam, J.C. Gody, D. Katzenstein, D.D. Koyalta, J.J. Kumwenda, M. Lallemant, L. Lynen, V.C. Marconi, N.A. Margot, S. Moussa, T. Ndung'u, P.N. Nyambi, C. Orrell, J.M. Schapiro, R. Schuurman, S. Sirivichayakul, D. Smith, M. Zolfo, M.R. Jordan, R.W. Shafer

Research output: Contribution to journalA1: Web of Science-articlepeer-review

Original languageEnglish
JournalJournal of Infectious Diseases
Issue numberS2
Pages (from-to)S70-S77
Publication statusPublished - 2013


  • Viral diseases
  • HIV
  • AIDS
  • Antiretrovirals
  • First-line drugs
  • Mutations
  • Nucleoside
  • Reverse transcriptase inhibitors
  • Drug resistance
  • Stavudine
  • Zidovudine
  • Tenofovir
  • Efavirenz
  • Duration
  • Review of the literature

Cite this